B. Riley Predicts Increased Earnings for Trevi Therapeutics

Key Points

• B. Riley has revised its earnings estimate for Trevi Therapeutics for FY2025, projecting a loss of ($0.42) per share, an improvement from the previous estimate of ($0.43).
• Despite a recent consensus earnings estimate of ($0.49) per share, various brokerages have assigned a "buy" rating with target prices ranging from $21.00 to $25.00 for Trevi Therapeutics stock.
• Trevi Therapeutics reported a quarterly earnings per share of ($0.09), beating the consensus estimate of ($0.10).

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - B. Riley upped their FY2025 earnings estimates for Trevi Therapeutics in a research report issued to clients and investors on Wednesday, August 13th. B. Riley analyst M. Mamtani now expects that the company will post earnings of ($0.42) per share for the year, up from their prior estimate of ($0.43). The consensus estimate for Trevi Therapeutics' current full-year earnings is ($0.49) per share. B. Riley also issued estimates for Trevi Therapeutics' Q4 2025 earnings at ($0.13) EPS, FY2026 earnings at ($0.60) EPS, FY2027 earnings at ($0.77) EPS, FY2028 earnings at ($0.93) EPS and FY2029 earnings at ($0.93) EPS.

A number of other equities research analysts have also weighed in on TRVI. D. Boral Capital restated a "buy" rating and issued a $21.00 target price on shares of Trevi Therapeutics in a report on Monday, June 2nd. Morgan Stanley initiated coverage on shares of Trevi Therapeutics in a report on Thursday. They issued an "overweight" rating and a $18.00 target price on the stock. Oppenheimer reiterated an "outperform" rating on shares of Trevi Therapeutics in a research note on Monday, June 2nd. Wall Street Zen lowered shares of Trevi Therapeutics from a "hold" rating to a "sell" rating in a research note on Friday, June 6th. Finally, HC Wainwright began coverage on shares of Trevi Therapeutics in a research note on Wednesday, May 28th. They issued a "buy" rating and a $21.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating and eight have given a Buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $20.11.

Trevi Therapeutics Stock Performance

Shares of NASDAQ TRVI traded up $0.2750 during trading on Monday, hitting $7.6950. 979,564 shares of the company traded hands, compared to its average volume of 1,805,410. The business's fifty day moving average is $6.73 and its 200 day moving average is $6.11. Trevi Therapeutics has a fifty-two week low of $2.36 and a fifty-two week high of $8.11. The firm has a market capitalization of $937.10 million, a price-to-earnings ratio of -18.30 and a beta of 0.58.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.01.

Institutional Trading of Trevi Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in TRVI. Alliancebernstein L.P. grew its holdings in Trevi Therapeutics by 19,064.5% in the 2nd quarter. Alliancebernstein L.P. now owns 4,281,355 shares of the company's stock worth $23,419,000 after acquiring an additional 4,259,015 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in Trevi Therapeutics during the fourth quarter worth about $17,099,000. Rubric Capital Management LP boosted its stake in Trevi Therapeutics by 88.0% during the second quarter. Rubric Capital Management LP now owns 8,531,860 shares of the company's stock worth $46,669,000 after acquiring an additional 3,993,325 shares in the last quarter. Octagon Capital Advisors LP bought a new stake in Trevi Therapeutics during the first quarter worth about $20,895,000. Finally, Frazier Life Sciences Management L.P. boosted its stake in Trevi Therapeutics by 44.5% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 10,664,774 shares of the company's stock worth $43,939,000 after acquiring an additional 3,283,684 shares in the last quarter. Hedge funds and other institutional investors own 95.76% of the company's stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.